5 July 2019:
Food protein-induced allergic proctocolitis (FPIAP) is a type of delayed inflammatory non-IgE mediated gut food allergy. Symptoms usually start at one to four weeks of age and range from having blood and/or mucous in bowel movements, to blood stained loose stools or diarrhoea. Infants with FPIAP are usually otherwise healthy and growing well. FPIAP mostly occurs in breastfed infants, but can also occur once a cow’s milk or soy based formula is commenced. The main triggers are cow’s milk or soy.
To provide more information about FPIAP, a new document is now available on the ASCIA website at
3 July 2019:
Last week the National Allergy Strategy launched the Nip Allergies in the Bub food allergy prevention project, which is funded by the Australian Government Department of Health.
The Nip Allergies in the Bub website www.preventallergies.org.au and other resources have been piloted over the past year in Western Australia. Feedback about the resources has been collected and improvements made, before the national launch. As well as online resources, face to face education of general practitioners, child maternal health nurses and pharmacists has been provided to inform and support health professionals, in preparation for the national launch.
The Nip Allergies in the Bub project aims to implement the ASCIA guidelines for infant feeding and allergy prevention, which can be found here: www.allergy.org.au/hp/papers/infant-feeding-allergy-prevention
14 June 2019:
Bayer Australia Ltd (Bayer) is advising healthcare professionals and consumers that limited stock of Novalac Allergy rice protein based formula will be available and released to pharmacies in Australia during June, July and August. Intermittent supply and limited availability in pharmacies across Australia will continue until supply returns to normal levels.
Novalac Allergy Infant Formula Supply Update June 201989.46 KB
11 June 2019:
It is with great pleasure that we confirm that an Order of Australia has been awarded to Professor Constance Katelaris AM, in recognition of her significant service to medicine in the field of immunology and allergy.
Professor Constance Katelaris AM has made substantial contributions to the fields of allergy and clinical immunology, the Australasian Society of Clinical Immunology and Allergy (ASCIA) and international allergy/immunology organisations. She has also authored and co-authored numerous publications on a wide variety of allergy and clinical immunology topics, is a regular invited speaker at national and international meetings and is acknowledged as an outstanding mentor to physicians training in allergy and clinical immunology.
Professor Katelaris has held several positions within ASCIA and international organisations, including:
Past President of the Australasian Society of Clinical Immunology and Allergy (ASCIA);
Secretary-General of the World Allergy Congress 2000 held in Sydney:
Chair of the ASCIA 2011 Conference held in Sydney;
Past President of the Asian Pacific Association of Allergology, Asthma and Clinical Immunology (APAAACI);
Editor of the Asia Pacific Allergy Journal;
- Executive positions on the World Allergy Organisation (WAO) Board.
As well as being Professor of Immunology and Allergy at Western Sydney University, and Head of Unit and Senior Staff Specialist at Campbelltown Hospital, Professor Katelaris is currently:
- Chair of the ASCIA HAE and CSU working parties;
- Deputy Chair of the ASCIA Drug Allergy committee;
- ASCIA representative on the Australian Prescriber journal as Immunology and Allergy sub-editor;
- Convenor of the Western Sydney University Graduate Certificate in Allergic Diseases;
- Chief investigator for Auspollen, the Australian Pollen Allergen Partnership.
We are therefore delighted that Professor Connie Katelaris has received an Order of Australia Award, in recognition of her significant contributions to improving the care of patients with allergy and other immune diseases.
31 May 2019:
The Murdoch Children’s Research Institute (MCRI) in Victoria is conducting a trial to evaluate probiotic and egg oral immunotherapy (OIT), which is a possible new treatment for egg allergy.
This trial is currently recruiting children and teenagers aged between 5 and 17 years, who live in Victoria and are allergic to egg.
28 May 2019:
With an outstanding program featuring 9 international speakers and a venue located on the spectacular Swan River in Perth, this conference is sure to be a highlight of the year for ASCIA members and other health professionals with an interest in allergy and clinical immunology.
To view the program go to https://www.ascia2019.com/program.php
To register go to https://www.ascia2019.com/registration.php
Discounted earlybird registration closes at midnight AEST on Monday 15 July 2019.
ASCIA 2019 Conference abstracts are invited for:
- ASCIA 2019 posters (displayed from Wednesday 4 to Friday 6 September 2019)
- ASCIA 2019 clinical grand rounds oral presentations (for advanced trainees only)
- ASCIA 2019 short oral presentations for ASCIA 2019 Conference (clinical research)
- Short oral presentation for CFAR Symposium (food allergy research)
Abstracts must be submitted at https://www.ascia2019.com/abstracts.php by midnight AEST on Monday 15 July 2019.
CFAR Symposium 2019: CFAR food allergy research abstracts will be selected to be included in the CFAR Symposium "Hot Publications" sessions. These will feature 3 minute presentations summarising food allergy research recently published or accepted for publication in peer-reviewed journals. Please submit an abstract and citation information (journal name, date accepted) in order to be considered. Selection will take into account journal impact factor and novelty of the work.
ASCIA-DAA Centre for Advanced Learning (CAL) Dietitians Course: This two day course on food allergy and intolerance will be held on Friday 6 and Saturday 7 September 2019. Pre-requisites for this course include completion of ASCIA anaphylaxis, food allergy, and food service etraining courses, all of which are available online free of charge. For information and to register for this course go to
ASCIA Dietitians Day: This event is being held on Thursday 5 September as part of the ASCIA 2019 Conference. There are no pre-requisites, but it is generally of most benefit to dietitians with experience with food allergy. Delegates can register just for this day, or combine it with day registration for Wednesday 4 September, registration for the CFAR Symposium on Tuesday 3 September and registration for the ASCIA-DAA CAL course (see above).
ASCIA-ANZAAG Drug Allergy Symposium: This Symposium is being held on Friday afternoon, as part of the ASCIA 2019 Conference. The 8th Australian and New Zealand Anaesthetic Allergy Group (ANZAAG) Symposium on “Perioperative allergy – A sensitive subject” is also being held in Perth, on Saturday 7 September 2019. To register for the Saturday Symposium go to http://www.anzaag.com/Events.aspx
24 May 2019:
ASCIA has updated its information on oral immunotherapy (OIT) for food allergy to include information from a meta-analysis (a method to combine data from multiple studies) of 12 OIT trials. This meta-analysis was published in the Lancet journal in April 2019 and is the most comprehensive and rigorous review of OIT for peanut allergy to date. OIT for food allergy is an emerging experimental treatment, and its benefits and harms are still being studied in clinical trials globally. The updated ASCIA article is available at:
Recent Lancet publication is a comprehensive review of OIT for peanut allergy
A meta-analysis that combined data from 12 OIT trials was published in the Lancet journal in April 2019. This is the most comprehensive and rigorous review of OIT for peanut allergy to date. It reviewed the effectiveness and safety of OIT for peanut versus placebo (in OIT study but in the group that was not given peanut) or peanut avoidance (patients not in OIT study).
Results showed that whilst OIT can achieve the goal of desensitisation for many people, those receiving OIT had more frequent allergic reactions, including anaphylaxis. They also required more frequent treatment with adrenaline (epinephrine) autoinjectors (such as EpiPen) than those who avoided peanut and did not receive OIT.
The Lancet publication supports the need for improved food allergy treatment approaches with an enhanced safety profile and trials focused on patient-important outcomes. ASCIA also supports this approach.